Sugi Predict

Sugi Predict / Compounds / SCHEMBL2956909

SCHEMBL2956909

SCHEMBL2956909

O=c1[nH]c2ccccc2c2[nH]c3ccccc3c12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 4/20 0.69
▸ KDM4E B2RXH2 5/20 0.57
▸ MEN1 O00255 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ TNKS O95271 2/20 0.57
▸ TNKS2 Q9H2K2 2/20 0.57
▸ LMNA P02545 2/20 0.57
▸ PARP1 P09874 2/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ GPR3 P46089 1/20 0.57
▸ BLM P54132 1/20 0.57
▸ PMP22 Q01453 1/20 0.57
▸ PARP15 Q460N3 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ CDK4 P11802 4/20 0.56
▸ CCND1 P24385 4/20 0.56
▸ PRKCA P17252 4/20 0.56
▸ MAPT P10636 3/20 0.56
▸ CDK5 Q00535 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14990329 0.88 PARP1 (0.64) CHEK1KDM4EMEN1KMT2AALDH1A1
SCHEMBL23132393 0.86 CHEK1 (0.73) CHEK1KDM4EMEN1KMT2AALDH1A1
SCHEMBL29391464 0.85 CHEK1 (0.66) CHEK1KDM4EMEN1KMT2AALDH1A1
SCHEMBL3236817 0.85 CHEK1 (0.66) CHEK1KDM4EMEN1KMT2AALDH1A1
SCHEMBL22478928 0.84 CHEK1 (0.56) CHEK1KDM4EMEN1KMT2AALDH1A1
SCHEMBL22478978 0.84 AHR (0.53) CHEK1KDM4EMEN1KMT2AALDH1A1
SCHEMBL23132413 0.84 CHEK1 (0.76) CHEK1KDM4EMEN1KMT2AALDH1A1
SCHEMBL22478919 0.83 CCNB2 (0.63) CHEK1KDM4EMEN1KMT2AALDH1A1
SCHEMBL22479042 0.83 CDK4 (0.63) CHEK1KDM4EMEN1KMT2AALDH1A1
SCHEMBL22457099 0.82 CHEK1 (0.68) CHEK1KDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298846-A1 Indolo[3,2-c]quinoline Compounds KAOHSIUNG MEDICAL UNIVERSITY (TW) 2009-12-03 — — US claimed
US-20220216424-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2022-07-07 — — US disclosed
WO-2020193447-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2020-10-01 — — WO disclosed
EP-2650274-B1 A thionation process and a thionating agent VIRONOVA THIONATION AB (SE) 2019-05-01 — — EP disclosed
US-9221855-B2 Thionation process and a thionating agent VIRONOVA THIONATION AB (SE) 2015-12-29 — — US disclosed
US-9221855-B2 Thionation process and a thionating agent VIRONOVA THIONATION AB (SE) 2015-12-29 — — US disclosed
US-9115158-B2 Thionating agent VIRONOVA THIONATION AB (SE) 2015-08-25 — — US disclosed
US-9115158-B2 Thionating agent VIRONOVA THIONATION AB (SE) 2015-08-25 — — US disclosed
US-20130303767-A1 THIONATING AGENT VIRONOVA THIONATION AB (SE) 2013-11-14 — — US disclosed
US-20130303767-A1 THIONATING AGENT VIRONOVA THIONATION AB (SE) 2013-11-14 — — US disclosed
US-20130102774-A1 THIONATION PROCESS AND A THIONATING AGENT VIRONOVA AB (SE) 2013-04-25 — — US disclosed
US-20130102774-A1 THIONATION PROCESS AND A THIONATING AGENT VIRONOVA AB (SE) 2013-04-25 — — US disclosed
US-8273760-B2 Indolo[3,2-c]quinoline compounds KAOHSIUNG MEDICAL UNIVERSITY (TW) 2012-09-25 — — US disclosed
WO-2012104415-A1 A THIONATION PROCESS AND A THIONATING AGENT VIRONOVA AB (SE) 2012-08-09 — — WO disclosed
EP-2484655-A1 A thionation process and a thionating agent Vironova AB (SE) 2012-08-08 — — EP disclosed
US-20100286163-A1 INDOLO[3,2-C]QUINOLINE COMPOUNDS Kaohsiung Medical Univeristy (TW) 2010-11-11 — — US disclosed
US-7763633-B2 Indolo[3,2-c]quinoline compounds KAOHSIUNG MEDICAL UNIVERSITY (TW) 2010-07-27 — — US disclosed
US-7763633-B2 Indolo[3,2-c]quinoline compounds KAOHSIUNG MEDICAL UNIVERSITY (TW) 2010-07-27 — — US disclosed
US-20090298846-A1 Indolo[3,2-c]quinoline Compounds KAOHSIUNG MEDICAL UNIVERSITY (TW) 2009-12-03 — — US disclosed
US-20090298846-A1 Indolo[3,2-c]quinoline Compounds KAOHSIUNG MEDICAL UNIVERSITY (TW) 2009-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298846-A1 Indolo[3,2-c]quinoline Compounds TERT, TERF2, CDKN1A CHEK1 246/4885KDM4E 1179/4885MEN1 855/4885
US-20130102774-A1 THIONATION PROCESS AND A THIONATING AGENT NT5M, NT5E, NUDT5 CHEK1 1770/4885KDM4E 4565/4885MEN1 954/4885
US-20130303767-A1 THIONATING AGENT NT5E, NT5C2, NUDT5 CHEK1 1929/4885KDM4E 4699/4885MEN1 664/4885
US-20220216424-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES OR10J3, EPCAM, L1CAM CHEK1 3991/4885KDM4E 1889/4885MEN1 1294/4885
US-20100286163-A1 INDOLO[3,2-C]QUINOLINE COMPOUNDS TERT, INMT, TERF2 CHEK1 264/4885KDM4E 949/4885MEN1 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.